Monoclonal antibodies in cancer immunotherapy

Kimiz‐Gebologlu, Ilgin; Gülce-İz, Sultan; Avci, Çığır Biray

doi:10.1007/s11033-018-4427-x

Cited by 160 publications

(108 citation statements)

References 43 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Monoclonal antibodies have been used extensively in cancer immunotherapy for their diversity and specificity generated through somatic recombination. The list of FDA-approved antibodies for cancer therapy continues to expand, including ones against cell surface antigens, such as human epidermal growth factor receptor 2 (HER2), programmed-death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and CD20, as well as soluble proteins, such as vascular endothelial growth factor (VEGF) and TNF [37] .…”

Section: Adaptive Immune Responsementioning

confidence: 99%

Cell-mediated immune resistance in cancer

Wang¹,

Hays²,

Rama³

et al. 2019

CDR

View full text Add to dashboard Cite

The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refractory to clinically established and experimental immunotherapies, including monoclonal antibodies and T cell-based therapies. From various forms of cytotoxic T cells to small molecule inhibitors that revamp the tumor microenvironment, these therapies have demonstrated notable responses in cancer models and a resistant subset of cancer patients, used both alone and in combination. However, even current approaches, such as those targeting checkpoint molecules, tumor ligands, and involving gene-related therapies, present a challenge in non-responding patients. In this perspective, we discuss the most common mechanisms of immune resistance, including tumor heterogeneity, tumor ligand and major histocompatibility complex modulation, anti-apoptotic pathways, checkpoint inhibitory ligands, immunosuppressive cells and factors in the tumor microenvironment, and activation-induced cell death. In addition, we discuss the strategies designed to circumvent these resistance pathways to showcase the potential of emerging technologies in battling the rise of resistance.

show abstract

Section: Adaptive Immune Responsementioning

confidence: 99%

Cell-mediated immune resistance in cancer

Wang¹,

Hays²,

Rama³

et al. 2019

CDR

View full text Add to dashboard Cite

show abstract

“…Immunotherapy has drastically evolved since the past 30 years, providing diverse approaches for boosting the intrinsic power of the host's immune system to target different diseases, especially cancer. This field includes a broad spectrum of strategies that includes the administration of cytokines, chemokines, monoclonal antibodies, cell lysates, and living cells (1)(2)(3)(4)(5)(6)(7) to directly or indirectly boost the immune system to fight cancer or to defuse it for mitigating transplant rejection (8), autoimmune diseases (9), or chronic inflammation (10).…”

Section: Introductionmentioning

confidence: 99%

Externally-Controlled Systems for Immunotherapy: From Bench to Bedside

et al. 2020

View full text Add to dashboard Cite

Immunotherapy is a very promising therapeutic approach against cancer that is particularly effective when combined with gene therapy. Immuno-gene therapy approaches have led to the approval of four advanced therapy medicinal products (ATMPs) for the treatment of p53-deficient tumors (Gendicine and Imlygic), refractory acute lymphoblastic leukemia (Kymriah) and large B-cell lymphomas (Yescarta). In spite of these remarkable successes, immunotherapy is still associated with severe side effects for CD19+ malignancies and is inefficient for solid tumors. Controlling transgene expression through an externally administered inductor is envisioned as a potent strategy to improve safety and efficacy of immunotherapy. The aim is to develop smart immunogene therapy-based-ATMPs, which can be controlled by the addition of innocuous drugs or agents, allowing the clinicians to manage the intensity and durability of the therapy. In the present manuscript, we will review the different inducible, versatile and externally controlled gene delivery systems that have been developed and their applications to the field of immunotherapy. We will highlight the advantages and disadvantages of each system and their potential applications in clinics.

show abstract

“…However, chemotherapeutic techniques are limited by their high cellular toxicity, as well as the occurrence of side effects [13]. Therefore, recent selection of biological agents to treat certain types of different tumors has attracted some attention for applications [14].…”

Section: Introductionmentioning

confidence: 99%

Structure and anticancer activity of a new lectin from the cultivated red alga, Kappaphycus striatus

Hung

Trinh

2020

J Nat Med

View full text Add to dashboard Cite

The red alga Kappaphycus striatus is economically important food species and extensively cultivated throughout most tropical parts of the world as a source of carrageenan. In this note, the primary structure of a new lectin KSL from this alga was elucidated by the rapid amplification method of complementary DNA (cDNA) ends, which consists of 267 amino acid residues distributed in four tandem-repeated domains of about 67 amino acids and sharing 43% of identity. The calculated molecular mass from the deduced sequence was consistent with that of natural KSL (27,826 Da) determined by electron spray ionization-mass spectrometry. The primary structure of KSL showed high similarity to those of the high mannose N-glycan specific lectins from marine red algae, ESA-2 from Eucheuma serra, EDA-2 from Eucheuma denticulatum, KSA-2 from Kappaphycus striatum, KAAs from Kappaphycus alvarezii and SfLs from Solieria filiformis, and from microorganisms, BOA from Burkholderia oklahomensis, MBHA from Myxococcus xanthus, OAA from Oscillatoria agardhii and PFL from Pseudomonas fluorescens. Furthermore, KSL showed anticancer effects against five carcinoma cell lines, HT29, Hela, MCF-7, SK-LU-1 and AGS, in a dose-dependent manner with the IC 50 values of 0.80-1.94 µM, whereas its inhibition activities on cancer cells were not detected in the presence of yeast mannan, an inhibitor against lectin KSL. The cultivated red alga K. striatus could also be a good source of functional lectin(s) for application as anticancer agents.

show abstract

Monoclonal antibodies in cancer immunotherapy

Cited by 160 publications

References 43 publications

Cell-mediated immune resistance in cancer

Cell-mediated immune resistance in cancer

Externally-Controlled Systems for Immunotherapy: From Bench to Bedside

Structure and anticancer activity of a new lectin from the cultivated red alga, Kappaphycus striatus

Contact Info

Product

Resources

About